These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 19878585

  • 1. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
    Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, Sobrinho-Simões M.
    BMC Cancer; 2009 Oct 31; 9():387. PubMed ID: 19878585
    [Abstract] [Full Text] [Related]

  • 2. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R.
    J Pathol; 2008 Feb 31; 214(3):320-7. PubMed ID: 18098337
    [Abstract] [Full Text] [Related]

  • 3. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 31; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M, Müller S, Britten M, Worm K, Schmid KW, Mann K, Fuhrer D.
    BMC Cancer; 2015 Mar 26; 15():184. PubMed ID: 25879531
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
    Henderson YC, Ahn SH, Kang Y, Clayman GL.
    Clin Cancer Res; 2008 Aug 01; 14(15):4908-4914. PubMed ID: 18676765
    [Abstract] [Full Text] [Related]

  • 6. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
    Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M.
    Oncogene; 2009 Jan 08; 28(1):85-94. PubMed ID: 18794803
    [Abstract] [Full Text] [Related]

  • 7. Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma.
    Jeong JH, Oh JM, Jeong SY, Lee SW, Lee J, Ahn BC.
    Thyroid; 2019 Apr 08; 29(4):540-548. PubMed ID: 30869573
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 9. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.
    Mol Cancer Ther; 2007 Mar 15; 6(3):1070-8. PubMed ID: 17363500
    [Abstract] [Full Text] [Related]

  • 10. Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
    Matsuse M, Mitsutake N, Tanimura S, Ogi T, Nishihara E, Hirokawa M, Fuziwara CS, Saenko VA, Suzuki K, Miyauchi A, Yamashita S.
    Int J Cancer; 2013 Feb 01; 132(3):738-43. PubMed ID: 22752848
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, Tang XD.
    Cancer Biol Ther; 2009 Sep 01; 8(18):1729-36. PubMed ID: 19633425
    [Abstract] [Full Text] [Related]

  • 12. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1623-9. PubMed ID: 16533790
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.
    Mol Cancer Ther; 2008 Apr 01; 7(4):890-6. PubMed ID: 18413802
    [Abstract] [Full Text] [Related]

  • 14. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
    Alzahrani AS, AlQaraawi A, Al Sohaibani F, Almanea H, Abalkhail H.
    Thyroid; 2012 May 01; 22(5):536-41. PubMed ID: 22435913
    [Abstract] [Full Text] [Related]

  • 15. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.
    Rahman MA, Salajegheh A, Smith RA, Lam AK.
    Exp Mol Pathol; 2015 Dec 01; 99(3):492-7. PubMed ID: 26403329
    [Abstract] [Full Text] [Related]

  • 16. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK.
    J Endocrinol; 2011 Oct 01; 211(1):79-85. PubMed ID: 21795305
    [Abstract] [Full Text] [Related]

  • 17. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
    Nucera C, Goldfarb M, Hodin R, Parangi S.
    Biochim Biophys Acta; 2009 Apr 01; 1795(2):152-61. PubMed ID: 19356676
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
    Rahman MA, Salajegheh A, Smith RA, Lam AK.
    Endocrine; 2016 Oct 01; 54(1):129-138. PubMed ID: 27179656
    [Abstract] [Full Text] [Related]

  • 19. V600EBRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells.
    Jiménez-Mora E, Gallego B, Díaz-Gago S, Lasa M, Baquero P, Chiloeches A.
    Int J Mol Sci; 2021 Jun 03; 22(11):. PubMed ID: 34204950
    [Abstract] [Full Text] [Related]

  • 20. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, Afaq F.
    Oncotarget; 2015 Sep 29; 6(29):28296-311. PubMed ID: 26299806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.